Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. Journal International Du Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, et al. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69(3):438–447.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63(1):4–15.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414–2422.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol [Internet]. 2006;49(3):466–477.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992–1001.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res. 2008;14(14):4400–4407.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013;109(6):1460–1466.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68–75.
   PubMed Web of Science ®Google Scholar
• Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52(6):1601–1609.
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531.
   PubMed Web of Science ®Google Scholar
• Fajkovic H, Halpern JA, Cha EK, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011;29(4):457–463.
   PubMed Web of Science ®Google Scholar
• Rink M, Crivelli JJ, Shariat SF, et al. Smoking and bladder cancer: a systematic review of risk and outcomes. Eur Urol Focus. 2015;1(1):17–27.
   PubMedGoogle Scholar
• Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006;50(6):1254–1262.
   PubMed Web of Science ®Google Scholar
• May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010;57(5):850–858.
   PubMed Web of Science ®Google Scholar
• Soukup V, Capoun O, Cohen D, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel systematic review. Eur Urol. 2017;72(5):801–813.
   PubMed Web of Science ®Google Scholar
• Moschini M, D’Andrea D, Korn S, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nature Reviews. Urology. 2017;14(11):651–668.
   PubMed Web of Science ®Google Scholar
• Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006;175(6):2048–2053.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Svatek RS, Tilki D, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010;105(10):1402–1412.
   PubMed Web of Science ®Google Scholar
• Mathieu R, Lucca I, Rouprêt M, et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nature Reviews. Urology. 2016;13(8):471–479.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Dalbagni G, Karnes RJ, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol. 2016;34(11):484.e19–484.e25.
   Web of Science ®Google Scholar
• Shariat SF, Zippe C, Lüdecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol. 2005;173(5):1518–1525.
   PubMed Web of Science ®Google Scholar
• Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12(24):7369–7373.
   PubMed Web of Science ®Google Scholar
• Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101(2):114–119.
   PubMedGoogle Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007;177(2):481–487.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010;28(4):389–400.
   PubMed Web of Science ®Google Scholar
• Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat. 2008;62(4):314–320.
   PubMed Web of Science ®Google Scholar
• Winget MD, Baron JA, Spitz MR, et al. Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform. 2003;70(1):41–48.
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6(9):678–686.
   PubMed Web of Science ®Google Scholar
• George B, Datar RH, Wu L, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007;25(34):5352–5358.
   PubMed Web of Science ®Google Scholar
• Du J, Wang S-H, Yang Q, et al. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol. 2016;14(1):137.
   PubMedGoogle Scholar
• Lu M-L, Wikman F, Ørntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002;8(1):171–179.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordón-Cardó C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 1994;152(2 Pt 1):388–392.
   PubMed Web of Science ®Google Scholar
• Sarkis A, Zhang Z, Cordoncardo C, et al. P53 nuclear overexpression and disease progression in ta-bladder carcinoma. Int J Oncol. 1993;3(2):355–360.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Weizer AZ, Green A, et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000;56(5):735–740.
   PubMed Web of Science ®Google Scholar
• Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999;5(12):4079–4084.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182(1):78–84– discussion 84.
   Web of Science ®Google Scholar
• Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20(4):445–459.
   PubMed Web of Science ®Google Scholar
• Tokunaga H, Shariat SF, Green AE, et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001;51(1):16–22.
   PubMed Web of Science ®Google Scholar
• Passoni NM, Shariat SF, Bagrodia A, et al. Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study. Bladder Cancer. 2016;2(1):91–99.
   PubMedGoogle Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, et al. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations. 2007;25(6):468–475.
   PubMed Web of Science ®Google Scholar
• Chade DC, Shariat SF, Adamy A, et al. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol. 2010;184(2):464–469.
   PubMed Web of Science ®Google Scholar
• Chade DC, Shariat SF, Godoy G, et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010;184(1):74–80.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kim J, Raptidis G, et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61(6):1140–1145.
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol [Internet]. 1999;36(5): 393–400.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Passoni N, Bagrodia A, et al. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int. 2014;113(1):70–76.
   PubMed Web of Science ®Google Scholar
• Passoni N, Gayed B, Kapur P, et al. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Urol Oncol. 2016;34(11):485.e7–485.e14.
   Google Scholar
• Santos L, Amaro T, Costa C, et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. International Journal of Cancer. Journal International Du Cancer. 2003;105(2):267–272.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res. 1999;59(13):3245–3250.
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Luque RJ, Menendez CL, et al. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II alpha, survivin, and E-cadherin. Hum Pathol. 2016;57:78–84.
   PubMed Web of Science ®Google Scholar
• Asakura T, Takano Y, Iki M, et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol. 1997;158(2):385–388.
   PubMed Web of Science ®Google Scholar
• Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol. 2006;59(1):83–88.
   PubMed Web of Science ®Google Scholar
• Ding W, Gou Y, Sun C, et al. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urol Oncol. 2014;32(1):42.e13–9.
   Web of Science ®Google Scholar
• Seo HK, Cho KS, Chung J, et al. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. Urology. 2010;76(2):512.e1–7.
   Web of Science ®Google Scholar
• van Rhijn BWG, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64(6):1911–1914.
   PubMed Web of Science ®Google Scholar
• Hernández S, López-Knowles E, Lloreta J, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res. 2005;11(15):5444–5450.
   PubMed Web of Science ®Google Scholar
• Hernández S, López-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664–3671.
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Cheney RT, Fischer G, et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur Journal Surgical Oncology: Journal Eur Soc Surg Oncol Br Assoc Surg Oncol. 2006;32(2):231–237.
   Google Scholar
• Pouessel D, Neuzillet Y, Mertens LS, et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol. 2016;27(7):1311–1316.
   PubMed Web of Science ®Google Scholar
• Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184(2):423–431.
   PubMed Web of Science ®Google Scholar
• Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol. 2000;299(3):551–572.
   PubMed Web of Science ®Google Scholar
• Rieger-Christ KM, Cain JW, Braasch JW, et al. Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol. 2001;32(1):18–23.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Pahlavan S, Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001;57(1):60–65.
   PubMed Web of Science ®Google Scholar
• Wang P, Lin SL, Zhang LH, et al. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer. Eur Journal Surgical Oncology: Journal Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40(3):255–259.
   Google Scholar
• Muramaki M, Miyake H, Terakawa T, et al. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol. 2012;30(2):161–166.
   PubMed Web of Science ®Google Scholar
• Abufaraj M, Shariat SF, Haitel A, et al. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2017;35(5):264–271.
   PubMed Web of Science ®Google Scholar
• Liu B, Miyake H, Nishikawa M, et al. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection. Urol Oncol. 2015;33(3):110.e11–8.
   Web of Science ®Google Scholar
• Karam JA, Lotan Y, Ashfaq R, et al. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70(3):482–486.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Karakiewicz PI, et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109(6):1106–1113.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Godoy G, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15(22):7012–7019.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Colombel M, Sundi D, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nature Reviews. Urology. 2017;14(4):244–255.
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Minervini A, Lapini A, et al. A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder. Applied Immunohistochemistry & Molecular Morphology: AIMM/official Publication of the Society for Applied Immunohistochemistry. 2013;21(3):218–227.
   PubMed Web of Science ®Google Scholar
• Krpina K, Babarović E, Jonjić N. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Archiv: an International Journal of Pathology. 2015;467(4):443–448.
   PubMed Web of Science ®Google Scholar
• Wang B, Wu S, Zeng H, et al. CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol. 2015;194(2):556–562.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Matsumoto K, Kim J, et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003;170(3):985–989.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kim J-H, Ayala GE, et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003;169(3):938–942.
   PubMed Web of Science ®Google Scholar
• Margulis V, Shariat SF, Ashfaq R, et al. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol. 2007;177(3):1163–1168.
   PubMed Web of Science ®Google Scholar
• Tadin T, Krpina K, Štifter S, et al. Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma. Diagn Pathol. 2012;7(1):152.
   PubMedGoogle Scholar
• van Rhijn BWG, Zuiverloon TCM, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433–441.
   PubMed Web of Science ®Google Scholar
• Mitra AP, Castelao JE, Hawes D, et al. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome a report from the Los Angeles Cancer Surveillance Program. Cancer. 2013;119(4):756–765.
   PubMed Web of Science ®Google Scholar
• Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014;65(4):742–754.
   PubMed Web of Science ®Google Scholar
• Wang LC, Xylinas E, Kent MT, et al. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urol Oncol. 2014;32(4):433–440.
   PubMed Web of Science ®Google Scholar
• Chaux A, Compérat E, Varinot J, et al. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection. Urology. 2013;81(1):116–122.
   PubMed Web of Science ®Google Scholar